Strontium Complexes for Pain Relief via Antioxidant Synergy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strontium-based formulations have limitations in effectively inhibiting acute and chronic sensory irritation, pain, and neuropathic conditions due to their limited potency and negative effects on biochemical pathways, leading to incomplete pain relief and potential side effects.
Innovation Solution
Development of strontium-containing complexes with cysteine-based antioxidants and polyhydroxyphenols, which form bipartite or tripartite compositions, including a polymer, to enhance strontium's therapeutic potency by inhibiting nociceptor activation pathways and reducing osmolarity, thereby improving pain and pruritus management.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topically applied strontium is used to inhibit acute sensory irritation and inflammation, then anti-irritant activity is improved, but negative effects on biochemical pathways increase
Solution Approach 1:
The patent combines strontium with cysteine-based antioxidants and polyhydroxyphenols to create a composite therapeutic agent. This composite formulation allows strontium to exert its anti-irritant effects while the accompanying antioxidants mitigate the negative effects on biochemical pathways, resolving the contradiction between therapeutic benefit and harmful side effects
Solution Approach 2:
Cysteine-based antioxidants and polyhydroxyphenols act as intermediary substances that modulate strontium's interaction with biochemical pathways. These intermediaries protect against harmful effects while allowing strontium's beneficial anti-irritant activity to proceed, effectively mediating between the therapeutic agent and the biological system
2Reliability
If strontium is used to treat neuropathic conditions, then pain inhibition is improved, but potency is insufficient
Solution Approach 1:
The patent merges strontium with cysteine-based antioxidants and polyhydroxyphenols in specific combinations to create enhanced therapeutic formulations. This merging of substances produces a synergistic effect where the combination achieves greater potency for neuropathic pain inhibition than strontium alone, resolving the insufficiency of strontium's standalone potency
3Reliability
If strontium formulations are applied topically, then acute sensory irritation is suppressed, but osmolarity causes side effects
Solution Approach 1:
The patent modifies the osmolarity parameter of strontium formulations by combining it with cysteine-based antioxidants and polyhydroxyphenols. This parameter change reduces the harmful osmolarity-related side effects while preserving strontium's ability to suppress sensory irritation, allowing for safer topical application
Data Source
AI summary
The present disclosure consists of therapeutically-active compositions that combine strontium with at least one additional molecules that increase the overall therapeutic potency of the combination beyond the potency of any of the separate constituents. Specifically, the combinations described herein perform two important functions; (1) they increase the ability of topically-applied strontium to inhibit both acute sensory irritation (e.g., pruritus and pain), redness, swelling and inflammation (collectively defined for purposes of this description, “irritation”) and the chronic irritation that is characteristic of and contributes to the development and maintenance of painful or pruritic neuropathic conditions; and (2) they decrease the strontium activated pathways that are known to enhance the development and maintenance of pain, pruritis and neuropathic conditions.